机构:[1]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[2]The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[3]Department of Urology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China[4]Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
Astragaloside IV(AS-IV), a saponin purified fromAstragalus membranaceus(Fisch.)Bge.var.mongholicus (Bge.)Hsiao, has been widely used in traditional Chinese medicine. However, the underlying mechanisms in treating chronic glomerular nephritis (CGN) have not been fully understood. The aim of the present study was to evaluate the potential mechanism of AS-IV on CGN. CGN rats were administrated with AS-IV at 10 mg center dot kg(-1)center dot d(-1)(ASL) and 20 mg center dot kg(-1)center dot d(-1)(ASH). Twenty four hour proteinuria, blood urea nitrogen (BUN), and serum creatinine (SCr) were detected. Hematoxylin-eosin (HE) and periodic acid-Schiff (PAS) staining were performed to evaluate the kidney lesion. Transmission electron microscope and GFP-RFP-LC3 transfection assay were used to monitor the effect of AS-IV on autophagy. IL-6 and IL-1 beta were detected. The expression of CyclinD1, PI3K/AKT/AS160 pathway and autophagy related proteins were detected by Western Blot. The results demonstrated that AS-IV improved kidney function, ameliorated kidney lesion, and diminished inflammatory in CGN rats. Further, both in vivo and vitro study demonstrated that AS-IV inhibited the proliferation of mesangial cells. AS-IV further displayed a remarkable effect on inhibiting the activation of PI3K/AKT/AS160 pathway and improved the activation of autophagy in vivo and vitro. These results suggested that AS-IV is a potential therapeutic agent for CGN and merits further investigation.
基金:
National Natural Science Foundation of China,
Grant/Award Numbers: 81603371, 81673874,
81974531; Natural Science Foundation of
Guangdong Province, Grant/Award Numbers:
2016A030310292, 2018A030313328);
TCM Science and Technology of Guangdong
Provincial Hospital of Chinese Medicine,
Grant/Award Number: YN2016YX04
第一作者机构:[1]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China
共同第一作者:
通讯作者:
通讯机构:[1]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China[2]The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou, China[*1]Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 232 WaiHuan East Road, Guangzhou University Town, Guangzhou 510006, China[*2]The Second Affiliated Hospital, Guangzhou University of Chinese Medicine, Guangzhou 510120, China
推荐引用方式(GB/T 7714):
Lu Ruirui,Chen Junqi,Liu Bihao,et al.Protective role of AstragalosideIVin chronic glomerulonephritis by activating autophagy throughPI3K/AKT/AS160pathway[J].PHYTOTHERAPY RESEARCH.2020,34(12):3236-3248.doi:10.1002/ptr.6772.
APA:
Lu, Ruirui,Chen, Junqi,Liu, Bihao,Lin, Hua,Bai, Lixia...&Wu, Junbiao.(2020).Protective role of AstragalosideIVin chronic glomerulonephritis by activating autophagy throughPI3K/AKT/AS160pathway.PHYTOTHERAPY RESEARCH,34,(12)
MLA:
Lu, Ruirui,et al."Protective role of AstragalosideIVin chronic glomerulonephritis by activating autophagy throughPI3K/AKT/AS160pathway".PHYTOTHERAPY RESEARCH 34..12(2020):3236-3248